Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
For the first time, DNA mutations in liver cells have been identified that impact metabolism and insulin sensitivity in patients with liver disease.
Hepatitis C virus thrives in humans for years, damaging the liver by causing chronic inflammation, eventually resulting in cirrhosis and liver cancer.
Results of national research pinpointed potential biomarkers that could ultimately be employed for the diagnosis of progressive stages of liver disease.
RNA molecules while carrying genetic instructions from DNA to the protein-making machinery of cells could help guard against non-alcoholic fatty liver.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD patients are at higher risk of developing Non-alcoholic steatohepatitis (NASH), which causes severe and chronic liver inflammation, fibrosis and liver damage.
A recent study by researchers at the University of Jyväskylä was successful in partially preventing fatty liver disease in rats.
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan. In order to change this unfortunate state of affairs, it is important to improve the prognosis of non-alcoholic fatty liver disease.
Human cells are encased by a membrane coated with diverse sugar molecules known as glycans. These glycans play many roles in health and disease, making them important to understand.
Excessive consumption of fructose -; a sweetener ubiquitous in the American diet -; can result in non-alcoholic fatty liver disease (NAFLD), which is comparably abundant in the United States.
Non-alcoholic fatty liver disease is the most common chronic liver disease in the world, with sometimes life-threatening consequences.
Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.
Diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) are all common diseases that can lead to serious health implications.
Mesenchymal stem cells, or MSCs, have the ability to differentiate into an array of different types of cells, such as fat, bone, and muscle cells.
For the first time, researchers at The Westmead Institute for Medical Research have identified and described a new and unique subset of human cells that are involved in the immune response against hepatitis B (HBV) infection. The discovery could help develop new treatments for HBV and inform future vaccine design.
Liver cancer is one of the deadliest cancers. It is insidious and does not present symptoms until it has progressed considerably, at which point, treatment options are limited and chances of survival are low. The most common type of liver cancer is hepatocellular carcinoma.